StockData
Akebia Therapeutics, Inc. logo

Akebia Therapeutics, Inc. (AKBA) stock analysis

AKBANasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 5, 2026Score 4/30
$0.57+0.03 (+5.89%)

Close on Nov 11, 2026Market cap $158.98MP/E –Yield –

StockData Score

Prices as of Nov 11, 2026How the score works

Value0Growth0Performance2Health2Dividend0

Weak4 of 30 checks passed

Akebia Therapeutics passes 4 of the 30 checks behind our score; 17 could not be run for lack of data and count as not passed. Each dot in the shape is one check — hover it for the numbers.

Valuation
0/6
Growth
0/6
Past performance
2/6
Financial health
2/6
Dividend
0/6

What stands out

  • Debt covered by cash flow

    Operating cash flow over the last twelve months equals 31.4% of total debt.

  • Net margin above its 5-year average

    Net margin was -22.6% over the last twelve months, against a 5-year average of -47.5%.

  • Net margin above the industry

    Akebia Therapeutics's net margin of -22.6% is above the Drugs median of -53.0%.

  • Short-term assets cover short-term debts

    Current assets are 1.36 times current liabilities.

What to watch

  • High debt

    Debt is 247% of shareholders' equity, above the 40% we consider low.

  • Revenue growing under 10% a year

    Revenue grew -6.9% a year over the last three fiscal years, short of the 10% we look for.

  • Elevated bankruptcy risk

    The Altman Z-score is -6.24; above 3 is the safe zone and below 1.8 the distress zone.

  • P/B above the industry

    Akebia Therapeutics's price-to-book of 7.80 is above the Drugs median of 2.29.

Valuation0/6

  • P/E against its history

    Not enough price and earnings history to compare.

  • P/E against the industry

    Needs positive earnings and enough profitable companies in the industry.

  • EV/EBITDA against its history

    Needs positive EBITDA and price history.

  • P/B above the industry

    Akebia Therapeutics's price-to-book of 7.80 is above the Drugs median of 2.29.

  • Price against fair value

    We could not estimate a fair value: it needs at least two valuation methods with positive inputs.

  • Margin of safety

    Depends on the fair value estimate.

Growth0/6

  • Revenue growing under 10% a year

    Revenue grew -6.9% a year over the last three fiscal years, short of the 10% we look for.

  • EPS growth over 3 years

    Needs positive EPS three years ago and today.

  • Earnings acceleration

    Needs positive net income now, a year ago and five years ago.

  • Growing slower than the industry

    Revenue grew -12.4% over the last twelve months; the Drugs median is 8.0%.

  • Guidance issued

    The latest outlook (Q4 2025 Vafseo net product revenue, Jan 12, 2026) was issued for the first time, so it neither adds nor takes away points.

  • Gross margin slipping

    Gross margin was 78.9% over the last twelve months, against 79.0% a year earlier.

Past performance2/6

  • Return on equity

    Needs positive equity and five years of results.

  • Return on invested capital

    Needs operating income and invested capital.

  • Return on equity below the industry

    Akebia Therapeutics's return on equity of -144% is below the Drugs median of -58.9%.

  • Earnings over 5 years

    Needs positive net income five years ago and in the latest year.

  • Net margin above its 5-year average

    Net margin was -22.6% over the last twelve months, against a 5-year average of -47.5%.

  • Net margin above the industry

    Akebia Therapeutics's net margin of -22.6% is above the Drugs median of -53.0%.

Financial health2/6

  • High debt

    Debt is 247% of shareholders' equity, above the 40% we consider low.

  • Debt rising against equity

    Debt to equity rose from 39.4% five years ago to 247%.

  • Debt covered by cash flow

    Operating cash flow over the last twelve months equals 31.4% of total debt.

  • Interest coverage

    Interest expense is not reported separately.

  • Short-term assets cover short-term debts

    Current assets are 1.36 times current liabilities.

  • Elevated bankruptcy risk

    The Altman Z-score is -6.24; above 3 is the safe zone and below 1.8 the distress zone.

Dividend0/6

  • No dividend

    Akebia Therapeutics has not paid a dividend in the last twelve months.

  • Yield against Treasuries

    No dividend.

  • Yield against the market

    No dividend.

  • Dividend stability

    No dividend.

  • Earnings cover

    No dividend.

  • Cash-flow cover

    No dividend.

Scores of similar companies

Fair value

How we estimate it

We don't publish a fair value for Akebia Therapeutics. It needs a US-dollar share price, at least two valuation methods with positive inputs (earnings, EBITDA, book value or sales) and, for companies with several share classes, classes that trade at the same price.

Valuation over time

Using the earnings and balance sheet published at each date, not today's.

  • P/B at month end
  • Own 5-year median 9.8
  • Drugs median 2.3

An estimate from reported numbers and market multiples, not a price target or investment advice. It can be far off for companies whose profits are about to change sharply.

Market risk

From the past year of daily prices.

Liquidity

Medium risk

Average value traded per day
$5.82M
Value traded per 1% price move
$1.27M

Downside

High risk

Typical loss in a bad month
39.7%
Volatility (annualized)
89%
Sharpe ratio, 1 year
-0.79
Beta to the S&P 500 (5Y)
1.12

Typical bad-month loss, week by week

25%: high

Margins

Share of revenue, fiscal years 2011 to 2025

Gross margin

83.3%+83.9 pts over 5 years

Operating margin

9.9%+138.2 pts over 5 years

Net margin

-2.3%+128.3 pts over 5 years

See a number that looks wrong?